IVF

The Howard and Georgeanna Jones Foundation for Reproductive Medicine supports Alabama infertility patients

Retrieved on: 
土曜日, 2月 24, 2024
Ethics, Education, Infertility, Reproductive medicine, Physician, Assisted reproductive technology, IVF, Supreme Court of Alabama, Fertilisation, Patient, Policy, Heart, Science, Research, Partnership

VIRGINIA BEACH, Va., Feb. 23, 2024 /PRNewswire/ -- The Howard and Georgeanna Jones Foundation for Reproductive Medicine ("Jones Foundation") was founded by IVF pioneers Dr. Howard W. Jones, Jr. and Dr. Georgeanna S. Jones who established the first in vitro fertilization program in the United States, the Jones Institute for Reproductive Medicine, that was responsible for the first American born IVF baby in 1981, and training many of today's leaders in the field.

Key Points: 
  • VIRGINIA BEACH, Va., Feb. 23, 2024 /PRNewswire/ -- The Howard and Georgeanna Jones Foundation for Reproductive Medicine ("Jones Foundation") was founded by IVF pioneers Dr. Howard W. Jones, Jr. and Dr. Georgeanna S. Jones who established the first in vitro fertilization program in the United States, the Jones Institute for Reproductive Medicine, that was responsible for the first American born IVF baby in 1981, and training many of today's leaders in the field.
  • "The ruling directly threatens Alabama reproductive medicine and infertility physicians and their patients.
  • The IVF therapy patients need in order to have a baby may be eliminated in Alabama and jeopardized in other U.S. states.
  • We must speak out and support reproductive medicine physicians and scientists and, especially, their patients."

Pozitivf Secures $20 Million in Funding Led by MonCap to Democratize Fertility Treatment for All

Retrieved on: 
木曜日, 2月 22, 2024
SAN, Embryology, Inception, Investment, Physician, Fertility, IVF, Growth, Public health, Paco, University, Master, Safety, RMA, Child

SAN ANTONIO, Feb. 22, 2024 /PRNewswire/ -- Pozitivf, a rapidly expanding fertility clinic network making industry-leading fertility treatment more accessible to all, announced today that it raised $20 million in growth funding. The capital raise, one of the most significant awarded in the space, was led by MonCap. MonCap's investment was made out of its dedicated fertility fund which represents one of the market's largest and most strategic pools of capital specifically committed to expanding access to fertility-related care.

Key Points: 
  • The capital raise, one of the most significant awarded in the space, was led by MonCap.
  • Currently, a single IVF cycle can range from $15,000 to $30,000, rendering the procedure inaccessible for the vast majority of the population.
  • Leveraging decades of experience, Pozitivf employs lean management principles with an extreme focus on treatment details and process workflows to eliminate variability and overhead.
  • "We will make fertility care accessible to the vast majority of families across the globe," said Jonathan Sockol, Managing Partner of MonCap.

Boston IVF Welcomes Dr. Meaghan Delaney to its Springfield Fertility Center, Expanding Access to Expert Care in Western Massachusetts

Retrieved on: 
火曜日, 2月 20, 2024
Boston University, Texas Children's Hospital, IUI, Hysterosalpingography, Medicine, MD, Telehealth, Semen analysis, IVF, Fertility, PCOS, REI, Patient, Pioneer Valley, Family, Medical Center, HSG, Birth control

SPRINGFIELD, Mass., Feb. 20, 2024 /PRNewswire-PRWeb/ -- Boston IVF, one of the world's most experienced fertility treatment providers, which has assisted in over 150,000 babies born since 1986, is pleased to announce the addition of reproductive endocrinologist, Dr. Meaghan Delaney, MD to its new fertility center in Springfield, MA.

Key Points: 
  • The addition of Dr. Meaghan Delaney to Boston IVF and its fertility clinic in Springfield enhances the accessibility of prompt reproductive care for those desiring to build a family.
  • "Dr. Delaney's return to western Massachusetts and commitment to patient well-being ensure seamless care, delivering invaluable advantages to our patients," stated David Stern, CEO of Boston IVF.
  • Dr. Delaney transitions to Boston IVF from her position as the Medical Director at the UMass Memorial Fertility Center in Worcester, MA.
  • "Dr. Delaney's return to western Massachusetts and commitment to patient well-being ensure seamless care, delivering invaluable advantages to our patients," stated David Stern, CEO of Boston IVF.

Seven Illume Fertility Specialists Receive Top Doctor Honors From Castle Connolly's America's Top Doctors® for 2024

Retrieved on: 
火曜日, 2月 20, 2024
Physician, Parent, Fertility, IVF, Birth rate, IUI, Patient, Nursing

NORWALK, Conn., Feb. 20, 2024 /PRNewswire-PRWeb/ -- Illume Fertility, a leading modern fertility practice whose exceptional quality of care helps hopeful parents grow their families, has announced that seven of their board-certified reproductive endocrinologists have been honored with the prestigious Castle Connolly Top Doctor award. For more than 30 years, the renowned publishing company Castle Connolly has compiled its list of America's Top Doctors®. Every doctor included on the list is nominated by peer doctors in their specific field and assessed by a physician-led research team.

Key Points: 
  • Castle Connolly's research methodology is designed to identify doctors who will achieve the best possible health outcomes for their patients.
  • For a reproductive endocrinologist, that translates to successful fertility treatment cycles (IUI and IVF) resulting in pregnancies and babies.
  • All seven Illume Fertility physicians are at the top of their field and have the most up-to-date knowledge and skills in the field of Reproductive Endocrinology, the medical specialty dedicated to fertility treatment.
  • *Illume's 2020 live birth rate per new patient for IVF patients 35 or under using own eggs, according to sart.org
    For more information about Illume Fertility, visit https://www.illumefertility.com/ .

Feminist narratives are being hijacked to market medical tests not backed by evidence

Retrieved on: 
木曜日, 2月 15, 2024
Breast cancer screening, Breast cancer, Woman, Pressure, Mass media, Marketing, BMJ, IVF, Female, Language, Feminism, Empowerment, Overdiagnosis, Fertility, Pregnancy, Risk, Health, Menopause, American College, Family, Tobacco, Breast, Hormone, MRI, AMH, Cancer, Birth control

In the 1980s, companies co-opted messaging about female autonomy to encourage women’s consumption of unhealthy commodities, such as tobacco and alcohol.

Key Points: 
  • In the 1980s, companies co-opted messaging about female autonomy to encourage women’s consumption of unhealthy commodities, such as tobacco and alcohol.
  • Today, feminist narratives around empowerment and women’s rights are being co-opted to market interventions that are not backed by evidence across many areas of women’s health.
  • Some of these health technologies, tests and treatments are useful in certain situations and can be very beneficial to some women.

The AMH test

  • The AMH test is a blood test associated with the number of eggs in a woman’s ovaries and is sometimes referred to as the “egg timer” test.
  • Although often used in fertility treatment, the AMH test cannot reliably predict the likelihood of pregnancy, timing to pregnancy or specific age of menopause.
  • Despite this, several fertility clinics and online companies market the AMH test to women not even trying to get pregnant.
  • Some use feminist rhetoric promising empowerment, selling the test as a way to gain personalised insights into your fertility.
  • 'Egg timer' tests can't reliably predict your chance of conceiving or menopause timing

    Our recent study found around 30% of women having an AMH test in Australia may be having it for these reasons.

Breast density notification


Breast density is one of several independent risk factors for breast cancer. It’s also harder to see cancer on a mammogram image of breasts with high amounts of dense tissue than breasts with a greater proportion of fatty tissue. While estimates vary, approximately 25–50% of women in the breast screening population have dense breasts.

  • Stemming from valid concerns about the increased risk of cancer, advocacy efforts have used feminist language around women’s right to know such as “women need to know the truth” and “women can handle the truth” to argue for widespread breast density notification.
  • Yet, there is no or little mention of the lack of robust evidence showing that it prevents breast cancer deaths.
  • While stronger patient autonomy is vital, campaigning for breast density notification without stating the limitations or unclear evidence of benefit may go against the empowerment being sought.

Ensuring feminism isn’t hijacked

  • But we need to ensure the goals of feminist health advocacy aren’t undermined through commercially driven use of feminist language pushing care that isn’t based on evidence.
  • Health professionals and governments must also ensure that easily understood, balanced information based on high quality scientific evidence is available.


Brooke Nickel receives fellowship funding from the National Health and Medical Research Council (NHMRC). She is on the Scientific Committee of the Preventing Overdiagnosis Conference. Tessa Copp receives fellowship funding from the National Health and Medical Research Council (NHMRC). She is also on the Scientific Committee of the Preventing Overdiagnosis Conference.

New Research from Maven Clinic Spotlights Global Demand for Fertility and Family Health Benefits

Retrieved on: 
水曜日, 2月 14, 2024
Anxiety, Woman, Family, ROI, Investment, Health, IVF, Pediatrics, Millennials, Generation Z, Fertility, Pregnancy, Menopause, HR, Parenting, Depression, AT&T, Partnership, Birth control

NEW YORK, Feb. 14, 2024 /PRNewswire/ -- Maven Clinic, the world's largest virtual clinic for women's and family health, today released its third annual State of Women's & Family Health Benefits report, providing a forecast for global fertility and family benefits trends in the year to come. Drawing on responses from over 1,200 HR leaders and 3,000 full-time employees across the U.S. and the U.K., the report provides employers with the insights needed to yield value from their benefits investments and attract top talent.

Key Points: 
  • Industry leaders like AT&T lead the pack, expanding Maven access for all employees to include fertility and family building support
    NEW YORK, Feb. 14, 2024 /PRNewswire/ -- Maven Clinic , the world's largest virtual clinic for women's and family health, today released its third annual State of Women's & Family Health Benefits report, providing a forecast for global fertility and family benefits trends in the year to come.
  • More companies are charting a path forward with women's and family health benefits that attract and retain talent of all ages and help manage costs.
  • Key findings from Maven's State of Women's & Family Health Benefits report include:
    Family benefits can make or break a career decision.
  • 75% of employers say reproductive health benefits are important for retention, and 57% of employees have taken, or might take, a job because it offered family or reproductive health benefits.

Castle Connolly Names 40 Physicians within The Prelude Network® as 2024 Top Doctors

Retrieved on: 
火曜日, 2月 13, 2024
Fertility preservation, IUI, Education, Reproductive medicine, Physician, Dream, IVF, Parent, Pleasure, Castle Connolly Medical, PGT, NYU, Faculty, Prelude, Vitrification, Artificial insemination, NYU Langone Health, Patient, Genetic testing, Nursing

HOUSTON, Feb. 13, 2024 /PRNewswire/ -- The Prelude Network® (Prelude), the largest and fastest-growing network of fertility providers in North America, today celebrates 40 of its physicians across 14 clinics within its expansive network who are named a 2024 Top Doctor by Castle Connolly.

Key Points: 
  • The recognition methodology has been vetted and endorsed by the Castle Connolly Medical Advisory Board .
  • Prelude specialists include innovators in fertility care who have pioneered some of today's most advanced reproductive technologies, including vitrification, fertility preservation, and preimplantation genetic testing (PGT).
  • Dr. Jamie Grifo , Program Director at NYU Langone Fertility and Chief Executive Physician of Inception, was named a 2024 Castle Connolly Top Doctor for the 25th year in a row.
  • "Inception Fertility extends its heartfelt congratulations to our incredible physicians who are so deserving of the Top Doctor recognition," says TJ Farnsworth, Founder and CEO of Inception Fertility.

HRC Fertility Center Adds Dr. Irene Woo to Its Roster of Prominent Doctors

Retrieved on: 
火曜日, 2月 13, 2024
Women, Hospitals, Baby, Maternity, Genetics, LGBTQ+, Practice Management, Health, Consumer, General Health, Gynaecology, Fertility preservation, MD, Reproductive technology, Fertility, IVF, HRC, Empathy, FACOG, Medicine, Patient, Journal, Patient safety, Environment, Diagnosis, Research, Book, Nursing

HRC Fertility Center (HRC), one of the largest providers of advanced fertility treatments based in Southern California, today announced the addition of Irene Woo, MD, FACOG , to its team of award-winning physicians.

Key Points: 
  • HRC Fertility Center (HRC), one of the largest providers of advanced fertility treatments based in Southern California, today announced the addition of Irene Woo, MD, FACOG , to its team of award-winning physicians.
  • Woo, an esteemed and compassionate medical professional holding dual board certifications in Obstetrics and Gynecology and Reproductive Endocrinology and Infertility, has joined the center’s Encino office.
  • “I became part of HRC due to its esteemed reputation and commitment to exemplary medical practices,” said Dr.
  • Woo.

Boston IVF Welcomes Reproductive Endocrinologist Jamil Mroueh, MD to its Rochester Fertility Center Team

Retrieved on: 
木曜日, 2月 8, 2024
SUNY Downstate Medical Center, American College, American University, Infertility, Greater, REI, MD, Patient, Fertility, IUI, PCOS, ACOG, Acquisition, Education, State university system, Health, IVF, Birth control

 ROCHESTER, Mass., Feb. 8, 2024 /PRNewswire-PRWeb/ -- Boston IVF, one of the world's most experienced fertility treatment providers, which has assisted in over 150,000 babies born since 1986, is pleased to announce that reproductive endocrinologist, Jamil Mroueh, MD has joined its fertility center in Rochester, NY.

Key Points: 
  • Dr. Jamil Mroueh's Arrival Bolsters Access to Prompt Reproductive Care at Boston IVF and its Rochester, NY Fertility Center.
  • "Dr. Mroueh's addition to Boston IVF's Rochester, NY fertility center represents a notable advantage for residents of the Greater Rochester Region and Western New York," stated David Stern, CEO of the Boston IVF fertility network.
  • Boston IVF's Rochester fertility center is located at 1561 Long Pond Rd Suite 410, Rochester, NY 14626 .
  • "Dr. Mroueh's addition to Boston IVF's Rochester, NY fertility center represents a notable advantage for residents of the Greater Rochester Region and Western New York," stated David Stern, CEO of the Boston IVF fertility network.

Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer

Retrieved on: 
火曜日, 2月 6, 2024
Business administration, Lead, Marketing, OvaScience, Spector, Patient, California State University, Employment, IVF, Compensated emancipation, Woman, CCO, Autoimmunity, Diabetes, Infertility, NASA, Johnson & Johnson, Pharmaceutical industry

ATLANTA, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead, late-clinical stage product candidate and innovative therapeutic and diagnostic products, today announced the appointment of Richard Spector to chief commercial officer (CCO), effective February 2024. Mr. Spector has 25 years of experience spanning a continuum of commercial stages at both public and private medical device and biopharmaceutical companies.

Key Points: 
  • Mr. Spector has 25 years of experience spanning a continuum of commercial stages at both public and private medical device and biopharmaceutical companies.
  • Mr. Spector has a Bachelor of Science degree in Business Administration and Marketing from California State University in Sacramento, CA.
  • This grant was approved by the Compensation Committee of Femasys’ Board of Directors and made as an inducement material to Mr. Spector entering into employment with Femasys as contemplated by Nasdaq Listing Rule 5635(c)(4).
  • Femasys provides this information in accordance with Nasdaq Listing Rule 5635(c)(4).